Current delivery of chemotherapy drugs to osteosarcoma is limited by the difficulties in overcoming the solid tumor microenvironment and the cardiotoxicity of doxorubicin (DOX). In previous work we found that phase separation could generate microspheres with high porosity. In this study, we applied these phase-separated porous microspheres as carriers for long-term anticancer drug delivery. Novel poly(propylene fumarate)-co-poly(l-lactic acid) microspheres incorporating DOX were fabricated by thermally induced phase separation. Following embedding into oligo(poly[ethylene glycol] fumarate) hydrogel, the composite system showed prolonged and pH-responsive release of DOX. In vitro cytotoxicity study using osteosarcoma 143B cells showed substantial long-term cytotoxic effects for up to 30 days. As a result, the DOX drug delivery hydrogel developed in this work may have significant potential as a long-term and localized chemotherapy device that would be sensitive to the acidic microenvironment of osteosarcoma and other cancers.
Impact Statement
A composite hydrogel embedded with porous microspheres fabricated by phase separation methods was developed and showed excellent long-term anticancer drug delivery capability to cancer cells.
Get full access to this article
View all access options for this article.
References
1.
TrédanO., GalmariniC.M., PatelK., and TannockI.F.Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst, 99, 1441, 2007.
2.
CrennV., BiteauK., AmiaudJ., et al.Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling. Am J Cancer Res, 7, 2333, 2017.
3.
SusaM., IyerA.K., RyuK., et al.Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma. Bmc Cancer, 9, 399, 2009.
4.
JaffeN.Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 152, 239, 2009.
5.
ChouA.J., GellerD.S., and GorlickR.Therapy for osteosarcoma: where do we go from here?. Pediatr Drugs, 10, 315, 2008.
6.
KagerL., DiakosC., and BielackS.Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?. Expert Opin Drug Metab Toxicol, 11, 1025, 2015.
7.
ZhangY., MaiQ., ZhangX., XieC., and ZhangY.Microenvironment signals and mechanisms in the regulation of osteosarcoma. In: HonokiK., and WeissK.R., eds. Osteosarcoma—Biology, Behavior and Mechanisms. London, UK: InTech, 2017, pp. 73–103.
8.
LuetkeA., MeyersP.A., LewisI., and JuergensH.Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev, 40, 523, 2014.
9.
ChatterjeeK., ZhangJ., HonboN., and KarlinerJ.S.Doxorubicin cardiomyopathy. Cardiology, 115, 155, 2010.
10.
TacarO., SriamornsakP., and DassC.R.Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol, 65, 157, 2013.
11.
EikenesL., TariM., TuftoI., BrulandO.S., de Lange DaviesC.Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer, 93, 81, 2005.
12.
van DalenE.C., MichielsE., CaronH.N., and KremerL.Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, 5, CD005006, 2010.
13.
NiuY., StadlerF.J., HeT., ZhangX., YuY., and ChenS.Smart multifunctional polyurethane microcapsules for the quick release of anticancer drugs in BGC 823 and HeLa tumor cells. J Mater Chem B, 5, 9477, 2017.
14.
KuangT., LiuY., GongT., PengX., HuX., and YuZ.Enzyme-responsive nanoparticles for anticancer drug delivery. Curr Nanosci, 12, 38, 2016.
15.
BarenholzY.C.Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release, 160, 117, 2012.
16.
El-KarehA.W., and SecombT.W.A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells. Neoplasia, 2, 325, 2000.
17.
BerrakS.G., EwerM.S., JaffeN., et al.Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep, 8, 611, 2001.
18.
RhaS.Y., ChungH.C., GongS.J., et al.Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma. Oncol Rep, 6, 631, 1999.
19.
O'dwyerP.J., ManolaJ., ValoneF.H., et al.Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule—an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol, 19, 2413, 2001.
20.
MinchintonA.I., and TannockI.F.Drug penetration in solid tumours. Nat Rev Cancer, 6, 583, 2006.
21.
KumariA., YadavS.K., and YadavS.C.Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces, 75, 1, 2010.
22.
TaH.T., DassC.R., LarsonI., ChoongP.F., and DunstanD.E.A chitosan-dipotassium orthophosphate hydrogel for the delivery of Doxorubicin in the treatment of osteosarcoma. Biomaterials, 30, 3605, 2009.
23.
TanM.L., FriedhuberA.M., DunstanD.E., ChoongP.F., and DassC.R.The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials, 31, 541, 2010.
24.
MaH., HeC., ChengY., et al.PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment. Biomaterials, 35, 8723, 2014.
25.
HollandT.A., TabataY., and MikosA.G.Dual growth factor delivery from degradable oligo (poly (ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J Control Release, 101, 111, 2005.
26.
WangS., LuL., and YaszemskiM.J.Bone-tissue-engineering material poly (propylene fumarate): correlation between molecular weight, chain dimensions, and physical properties. Biomacromolecules, 7, 1976, 2006.
27.
FisherJ.P., HollandT.A., DeanD., EngelP.S., MikosA.G.Synthesis and properties of photocross-linked poly(propylene fumarate) scaffolds. J Biomater Sci Polym Ed, 12, 673, 2001.
28.
DhandayuthapaniB., YoshidaY., MaekawaT., and KumarD.S.Polymeric scaffolds in tissue engineering application: a review. Int J Polym Sci, 2011, 1, 2011.
29.
TemenoffJ.S., AthanasiouK.A., LebaronR.G., and MikosA.G.Effect of poly (ethylene glycol) molecular weight on tensile and swelling properties of oligo (poly (ethylene glycol) fumarate) hydrogels for cartilage tissue engineering. J Biomed Mater Res, 59, 429, 2002.
30.
ShinH., Quinten RuhéP.Q., MikosA.G., and JansenJ.A.In vivo bone and soft tissue response to injectable, biodegradable oligo (poly (ethylene glycol) fumarate) hydrogels. Biomaterials, 24, 3201, 2003.
31.
LiuX., ChenW., GustafsonC.T., et al. Tunable tissue scaffolds fabricated by in situ crosslink in phase separation system. RSC Adv, 5, 100824, 2015.
32.
LiuX., MillerA.L., WaletzkiB.E., YaszemskiM.J., and LuL.Novel biodegradable poly(propylene fumarate)-co-poly(l-lactic acid) porous scaffolds fabricated by phase separation for tissue engineering applications. RSC Adv, 5, 21301, 2015.
33.
WangS., KempenD.H., YaszemskiM.J., and LuL.The roles of matrix polymer crystallinity and hydroxyapatite nanoparticles in modulating material properties of photo-crosslinked composites and bone marrow stromal cell responses. Biomaterials, 30, 3359, 2009.
34.
BudyantoL., GohY.Q., and OoiC.P.Fabrication of porous poly (L-lactide) (PLLA) scaffolds for tissue engineering using liquid–liquid phase separation and freeze extraction. J Mater Sci Mater Med, 20, 105, 2009.
35.
BurkeS.A., Ritter-JonesM., LeeB.P., and MessersmithP.B.Thermal gelation and tissue adhesion of biomimetic hydrogels. Biomed Mater, 2, 203, 2007.
36.
RyuJ.H., LeeY., KongW.H., KimT.G., ParkT.G., and LeeH.Catechol-functionalized chitosan/pluronic hydrogels for tissue adhesives and hemostatic materials. Biomacromolecules, 12, 2653, 2011.
37.
RoseS., PrevoteauA., ElzièreP., HourdetD., MarcellanA., and LeiblerL.Nanoparticle solutions as adhesives for gels and biological tissues. Nature, 505, 382, 2014.
38.
da Silva GomesG., de AlmeidaA.T., KosakaP.M., et al.Cellulose acetate propionate coated titanium: characterization and biotechnological application. Mat Res, 10, 469, 2007.
39.
KunduA.K., GelmanJ., and TysonD.R.Composite thin film and electrospun biomaterials for urologic tissue reconstruction. Biotechnol Bioeng, 108, 207, 2011.
40.
LiuX., MillerA.L., FundoraK.A., YaszemskiM.J., and LuL. Poly (ɛ-caprolactone) dendrimer cross-linked via metal-free click chemistry: injectable hydrophobic platform for tissue engineering. ACS Macro Lett, 5, 1261, 2016.
